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SUMMARY ∑ Hyponatremia is the most common electrolyte disorder. Sometimes it is not easy to
consider the differential diagnosis and to establish a final diagnosis. Hyponatremia is acute severe (less
than 115 mmol/L) when lasting for 36 to 48 hours. This condition is a medical emergency because
these patients have pronounced symptoms as the result of brain edema. It should be rapidly corrected
to approximately 130 mmol/L to prevent permanent brain damage. In chronic severe hyponatremia,
the symptoms are mild and there is no brain edema. Many authors recommend correction to approxi-
mately 130 mmol/L at a rate of less than 0.5 mmol/h, to minimize the risk of cerebral myelinolysis. In
the near future, vasopressin antagonists will become available. Preliminary experience has already dem-
onstrated their efficacy in inducing sustained water diuresis and correction of hyponatremia.
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Introduction
Hyponatremia is the most common electrolyte disor-
der in clinical medicine. However, physicians do not al-
ways find it easy to consider the differential diagnosis and
to establish a final diagnosis. In almost all cases, hy-
ponatremia results from the intake and subsequent reten-
tion of water1. The water load will, in normal subjects, be
rapidly excreted as the dilutional fall in plasma osmolal-
ity suppresses the release of antidiuretic hormone (ADH),
thereby allowing the excretion of diluted urine.
Causes of Hyponatremia
There are many causes of hyponatremia, however, in
almost all cases it occurs because there is an impairment
in the renal excretion of water, usually due to inability to
suppress ADH release (Table 1).
Disorders in which ADH  levels are elevated
The two most common causes of hyponatremia are
effective circulating volume depletion and the syndrome
of inappropriate ADH secretion, disorders in which ADH
secretion is not suppressed.
Effective circulating volume depletion
Significantly decreased tissue perfusion is a potent
stimulus to ADH release. This response is mediated by
baroreceptors in the carotid sinus, which sense a reduc-
tion in pressure or stretch, and can overcome the inhibi-
tory effect of hyponatremia on ADH secretion. Thus,
hyponatremia may develop in patients with any of the
following disorders: 1) true volume depletion due to vom-
iting, diarrhea; 2) bleeding or urinary losses; 3) conges-
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tive heart failure and cirrhosis; and 4) resulting compli-
cation of therapy with thiazide diuretics1,2.
Syndrome of inappropriate ADH secretion
Persistent ADH release and water retention can also
be seen in a variety of disorders that are not associated
with hypovolemia. The pattern of ADH release in these
conditions is variable.
Hormonal changes
Hyponatremia can occur in patients with adrenal in-
sufficiency (who suffer a lack of cortisol that is responsible
for hyponatremia) and hypothyroidism.
Disorders in which ADH levels may be appropriately
suppressed
There are two disorders in which hyponatremia can
occur despite suppression of ADH release. These condi-
tions are advanced renal failure and primary polydipsia.
Advanced renal failure
The relative ability to excrete free water (free water
excretion divided by the glomerular filtration rate) is
maintained in patients with mild to moderate renal fail-
ure3. Thus, normonatremia is usually maintained in the
absence of oliguria or advanced renal failure. In the latter
setting, the minimum urine osmolality rises to 200-250
mosmol/kg despite appropriate suppression of ADH. The
osmotic diuresis induced by the increased solute excretion
per functioning nephron is thought to be responsible for
the inability to dilute urine3.
Primary polydipsia
Primary polydipsia is a disorder in which there is a
primary stimulation of thirst. It is most often seen in anx-
ious, middle-aged women, and in patients with psychiatric
illnesses, particularly those taking antipsychotic drugs in
whom the common side effect of dry mouth leads to an
increased water intake4,5.
Low dietary solute intake
Beer drinkers or other malnourished patients (includ-
ing those with low-protein, high-water diets) may have a
marked reduction in the water excretory capacity that is
directly mediated by poor dietary intake. Beer contains
little or no sodium, potassium, or protein, and the carbo-
hydrate load will suppress endogenous protein breakdown
and therefore urea excretion. As a result, daily solute ex-
cretion may fall below 250 mosmol/kg, leading to a reduc-
tion in the maximum urine output to below 4 L/day, even
though the urine being appropriately diluted. Hyponatre-
mia will ensue if more than this amount of fluid is taken.
Table 1. Major causes of hyponatremia
Disorders in which ADH levels are elevated
∑ Effective circulating volume depletion
True volume depletion
Congestive heart failure and cirrhosis
Thiazide diuretics





Disorders in which ADH levels may be appropriately suppressed




∑ High plasma osmolality ∑ hyperglycemia, mannitol, urea in renal failure
∑ Normal plasma osmolality ∑ hyperlipidemia, hyperproteinemia, glycine solution
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Pseudohyponatremia
Pseudohyponatremia refers to those disorders in
which hyponatremia is associated with a plasma osmola-
lity that is normal or elevated but not reduced.
High plasma osmolality
This condition is most often due to hyperglycemia or
the administration and subsequent retention of hypertonic
mannitol. In these settings, the rise in plasma osmolality
induced by glucose or mannitol drives water out of cells,
thereby lowering the plasma sodium concentration by di-
lution.
Renal failure is another disorder in which hyponatre-
mia may be associated with high plasma osmolality (due
to the retention of urea). However, urea is an ineffective
osmole, since it can freely cross cell membranes. Thus,
urea accumulation does not lead to water movement out
of the cells, and these patients have true hyponatremia.
Normal plasma osmolality
Hyponatremia associated with normal plasma osmo-
lality can occur when there is a reduction in the fraction
of plasma that is water. In normal subjects, the plasma
water is approximately 93% of the plasma volume, with
fats and proteins accounting for the remaining 7%. Thus,
a normal plasma sodium concentration of 142 mmol/L
actually represents a concentration in the physiologically
important plasma water of 154 mmol/L. However, the
plasma water fraction may fall below 80% in patients with
marked hyperlipidemia (as with latescent serum in uncon-
trolled diabetes mellitus) or hyperproteinemia (as in mul-
tiple myeloma). In these settings, the plasma water so-
dium concentration and plasma osmolality are unchanged,
but the measured sodium concentration in the total
plasma volume will be reduced (since the specimen con-
tains less plasma water).
Symptoms of Hyponatremia
Acute severe hyponatremia and cerebral edema
Serum sodium concentration of less than 115 mmol/
L is by some arbitrarily defined as severe hyponatremia,
whereas the term ‘acute’ commonly indicates a duration
of hyponatremia of less than 36-48 hours. Untreated acute
severe hyponatremia is associated with high morbidity
and mortality rates, both of which are primarily ascribed
to brain edema.
The symptoms directly attributable to hyponatremia
primarily occur with acute and marked reduction in the
plasma sodium concentration, and reflect neurologic dys-
function induced by cerebral edema1,6,7. In this setting, the
associated fall in plasma osmolality creates an osmolal
gradient that favors water movement into the cells, lead-
ing in particular to brain edema.
Hyponatremia-induced cerebral edema occurs prima-
rily with rapid (in 1-3 days) reduction in the plasma so-
dium concentration7, as most often occurs in postopera-
tive patients given large amounts of hypotonic fluid and
in those treated with thiazide diuretics5,6.
The presence of cerebral overhydration generally cor-
relates closely with the severity of symptoms6. Nausea and
malaise are the earliest symptoms, and may be seen when
the plasma sodium concentration falls below 125-130
mmol/L. These may be followed by headache, lethargy
and obtundation, and eventually seizures, coma and res-
piratory arrest if the plasma sodium concentration falls
below 115-120 mmol/L6,8.
Animal experiments have facilitated analysis of the
probable causes of cerebral edema in severe acute hy-
ponatremia. That work has demonstrated that brain cells
have the ability to adapt to hypo-osmolality-induced cell
swelling, as most other cells do9. However, this process
requires 48-72 hours to reach completion9. An initial
phase of rapid extrusion of ions (Na+, K+, and Cl-) from
the cells is followed by a slow phase during which the in-
tracellular concentrations of osmotically active organic
osmolytes are reduced10,11. This regulatory process serves
to return the initially swollen cells to normal cell volume
(Fig. 1). During the transitional phase, before the cell
volume adaptation is complete, brain edema is present
(Fig. 2). Because of the rigid skull surrounding the brain,
cerebral edema can lead to decreased brain perfusion and
herniation of the brainstem into the foramen magnum.
These changes are preventable by rapid correction of acute
severe hyponatremia.
Chronic severe hyponatremia and risk of myelinolysis
Chronic severe hyponatremia often involves mild to
moderate hyponatremic symptoms. It is commonly ob-
served in the advanced stages of the syndrome of inappro-
priate secretion of antidiuretic hormone, cardiac failure,
and liver cirrhosis. It does not appear to cause major prob-
lems by itself. In chronic hyponatremia, brain volume
regulation is intact, and thus there is no evidence of brain
edema.
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Fig. 1. Cerebral adaptation to hyponatremia
Decrease in extracellular osmolality causes movement of water (H2O) into the cells, increasing intracellular volume and thus causing tissue
edema. To prevent this, the mechanisms geared towards volume regulation come into operation. Soon after the induction of extracellular
fluid hypo-osmolality, H2O moves into the brain in response to osmotic gradient. The result is cerebral edema. Within 1-3 hours, a decrease
in cerebral extracellular volume occurs by fluid movement into the cerebrospinal fluid, which is then shunted back into the systemic circula-
tion. This happens very promptly, as early as 30 minutes after the onset of hyponatremia. As H2O losses accompany the losses of brain solute,
the expanded brain volume decreases back towards normal.
Fig. 2. Computer tomography scans of the brain
(A) A normal appearing brain on CT scan; (B) diffuse cerebral edema in a patient with acute severe hyponatremia.
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Problems may arise when chronic hyponatremia is
corrected, especially when it is corrected faster than 0.5
mmol/h, and when the correction process eventually
reaches the normonatremic or even hypernatremic range.
An overly rapid increase in the plasma sodium concentra-
tion may lead to the osmotic demyelination syndrome
(also called central pontine myelinolysis, although
demylination is often more diffuse and does not necessar-
ily involve the pons)6,7,12,13 (Fig. 3). These changes may
lead to potentially severe neurologic symptoms that are
delayed by 2-6 days after correction and may be irrevers-
ible13.
It should be pointed out that correction of chronic
hyponatremia is often an elective procedure, because there
are no pernicious symptoms or adverse events related to
this form of hyponatremia. Although data are incomplete,
there is more evidence favoring slow correction of chronic
severe hyponatremia than those favoring rapid correction.
Pontine and central pontine myelinolysis involves
changes that produce the clinical signs of bulbar and
Fig. 3. Magnetic resonance imaging
(A) A normal appearing pons on MRI; (B) image of central pontine myelinolysis. MRI is the most useful diagnostic technique for central
pontine myelinolysis.
pseudobulbar palsy. Imaging studies such as computed
tomography (CT) and magnetic resonance imaging
(MRI) are helpful in actually demonstrating that myeli-
nolysis has occurred14. However, CT and MRI results
become positive only 6 to 10 days after the clinical signs
of myelinolysis have become manifest. There is no known
treatment for this demyelination syndrome.
In fact, as the term ‘osmotic demyelination’ suggests,
in animal studies it was possible to directly relate myeli-
nolysis to local osmotic imbalances that occur in the brain
during rapid correction of chronic hyponatremia15. These
imbalances have been attributed to slow reaccumulation
of cell protective organic osmolytes, as opposed to rapid
and overshooting reaccumulation of ionic osmolytes. In
experimental animals, it has been  demonstrated that dis-
ruption of the blood ∑ brain barrier may occur in situa-
tions such as this, leading to myelinolysis. Because of re-
gional differences in the brain, the pons is a preferred site
for the blood ∑ brain barrier disruption and associated
myelinolysis.
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Diagnosis of Hyponatremia
The diagnostic process in hyponatremia involves thor-
ough history and physical examination along with three
basic laboratory values: serum osmolality, urine osmolal-
ity, and urine sodium1 (Fig. 4). This information is used
to determine the cause of hyponatremia and to help guide
therapy. It is necessary to ask patients about the use of
medications (particularly thiazide diuretics), recent vom-
iting, diarrhea, or excessive sweating with hypotonic fluid
ingestion, recent surgery, a history of physiatric illness,
congestive heart failure (CHF), cirrhosis, or nephrotic
syndrome with renal failure. Physical examination should
focus on assessment of volume status and include ortho-
static vital signs, skin turgor, mucous membrane appear-
ance, jugular vein distention, findings of edema, and
wedge pressure and central venous pressure if available.
The initial laboratory measurement needed in the
evaluation of hyponatremia is serum osmolality. A com-
mon cause of hyperosmolar hyponatremia (serum osmo-
lality below 290 mmol/L) is hyperglycemia. The infusion
of hypertonic mannitol is a less common cause. Isoosmolar
hyponatremia (normal serum osmolality of 275 to 290
mmol/L) may rarely be caused by pseudohyponatremia
from either severe hyperlipidemia or hyperproteinemia.
The findings result from the method used to measure
serum sodium concentration and do not represent true
hyponatremia.
Hypo-osmolar hyponatremia (serum osmolality less
than 275 mmol/L) is the most common type.
The next laboratory measurement is urine osmolality.
This value indicates whether water excretion is impaired.
Patients with hyponatremia and urine osmolality less than
100 mmol/L are appropriately excreting very diluted
urine, as in primary polydipsia and resetting of the
osmostat (i.e. a form of the syndrome of inappropriate
ADH in which serum osmolality is reset downward to a
new threshold). In patients with resetting of the osmotat,
a serum sodium concentration between 125 and 130
mmol/L is usually maintained, with appropriate excretion
of diluted urine during water loading. However, most
patients with hyponatremia have urine osmolality of more
than 200 mmol/L, reflecting impairment in water excre-
tion.
The final step in the evaluation of hyponatremia is to
measure the urine sodium concentration and to use this
Fig. 4. Diagnostic algorithm for hyponatremia
Assessment of volume status
Euvolemia (no edema)
• Total body water
• Total bodu sodium
U\a>20U\a<20UNa>20 U\a>20 UNa<20
Hypervolemia
• Total body water
• Total body sodium
Hypovolemia
• Total body water
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finding in conjunction with volume status to determine
the cause of hyponatremia. A spot test showing a urine
sodium concentration of less than 30 mmol/L differenti-
ates patients with hypovolemic hyponatremia from pa-
tients with euvolemic hyponatremia.
A high urine sodium concentration may be found in
patients with volume depletion secondary to a renal cause
of salt wasting (e.g., adrenal insufficiency, use of thiazide
diuretics), metabolic alkalosis, or osmotic diuresis (e.g.,
from hyperglycemia). The so-called sodium-avid states of
CHF, cirrhosis, and nephrotic syndrome all typically have
a low urine sodium concentration unless patients are tak-
ing a diuretic, whereas renal failure tends to cause a high
urine sodium concentration.
Treatment of Hyponatremia
The preferred rate at which the plasma sodium con-
centration should be elevated varies with the clinical pre-
sentation (Fig. 5). Acute symptomatic hyponatremia pri-
marily results from cerebral edema due to water movement
into the brain. Rapid initial correction of hyponatremia
is warranted in symptomatic patients, but overly rapid
correction can be deleterious in any patient, particularly
those with chronic hyponatremia (Tables 2 and 3).
Asymptomatic hyponatremia
Untreated patients with chronic asymptomatic hy-
ponatremia are generally at a low risk of neurologic symp-
toms owing to the cerebral adaptation. In this setting,
rapid correction is not indicated and may be harmful. The
focus of therapy should be on identifying and correcting
Fig. 5. Treatment algorithm for severe hyponatremia (<125 mmol/L)











Hypertonic saline 1-2 mL/kg/h
Coadministration of furosemide
Some immediate correction needed
Hypertonic saline 1-2mL/kg/h
Coadministration of furosemide
Change to water restriction upon 10% increase of
sodium or if symptoms resolve
Perform frequent measurement of serum and urine
electrolytes
Do not exceed 1.5 mmol/L/h or 20 mmol/d
Long-term management identification and
treatment of reversible causes
Water restriction
Demeclocycline, 300-600 mg bid
Urea, 15-60 g/d
V2 receptor antagonists
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Table 2. General guidelines for the treatment of symptomatic hyponatremia
Acute hyponatremia (duration less than 48 hours)
Increase serum sodium rapidly by approximately 2 mmol/L/h until symptoms resolve
Full correction probably safe but not necessary
Chronic hyponatremia (duration of more than 48 hours)
Initial increase in serum sodium by 10% or 10 mmol/L
Perform frequent neurologic evaluations; correction rate may be reduced with improvement of symptoms
At no time should correction exceed the rate of 1.5 mmol/L/h, or increments of 15 mmol/d
Measure serum and urine electrolytes every 1-2 h
*The sum of urinary cations (UNa + UK) should be less than the concentration of infused sodium to ensure excretion of electrolyte-free water.
Table 3. Treatment of chronic symptomatic hyponatremia
∑ Calculate the net water loss needed to raise serum sodium (SNa) from 110 mmol/L to 120 mmol/L in a 50-
kg person.
Example
Current SNa x Total body water (TBW) = Desired SNa x New TBW
Assume that TBW = 60% of body weight
Therefore TBW of patient = 50 x 0.6 = 30 L
New TBW = 110 mmol/Lx30 L/120 mmol/L = 27.5 L
Thus, the electrolyte-free water loss needed to raise SNa to 120 mmol/L = Present TBW ∑ New TBW = 2.5 L
∑ Calculate the time course in which to achieve the desired correction (1 mmol/h) ∑ in this case, 250 mmol/h
∑ Administer furosemide, monitor urine output, and replace sodium, potassium, and excess free water lost in
urine
∑ Continue monitoring urine output and replace sodium, potassium, and excess free water lost in urine
the underlying cause of hyponatremia. It the patient is
judged to be hypovolemic on the basis of clinical assess-
ment and urine sodium concentration, normal saline so-
lution should be administered initially to correct the ex-
tracellular fluid volume deficit. Hypovolemic patients
should restrict salt and water.
Most patients with CHF or nephrotic syndrome
maintain a serum sodium concentration of more than 125
mmol/L, even with a marked increase in ADH levels.
Patients with CHF can be treated with inotropes,
afterload reduction, and loop diuretics in addition to salt
and water restriction. Loop diuretics are the mainstay of
therapy in patients with nephrotic syndrome, and if these
agents are unsuccessful, dialysis may be warranted.
For patients who are euvolemic and hyponatremic,
therapy consists primarily of water restriction.
Symptomatic hyponatremia
More aggressive initial correction, at a rate of 1.5 to 2
mmol/L per hour, is indicated for the first three to four
hours (or until the symptoms resolve) in the patients who
present with seizures or other severe neurologic abnor-
malities due to untreated and usually acute hyponatre-
mia7,15,16. The primary problem in these patients is cere-
bral edema, and the risk of delayed therapy is greater than
the potential risk of too rapid correction.
Hyponatremia can be corrected with the administra-
tion of hypertonic saline solution (3%) at a rate of about
1 ml/kg per hour. A loop diuretic may be added to enhance
water excretion if urine osmolality is greater than 300
mOsm/kg. With the use of this combination therapy, the
sodium lost in the urine is replaced with an equal amount
of sodium in a smaller volume. The serum sodium con-
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centration should be raised by no more than 25 mmol/L
in the first 48 hours, at a rate of no more than 2 mmol/L
per hour, and the target goal should be 120 to 125 mmol/
L. Treatment with hypertonic saline solution is advocated
only for patients with severe hyponatremia who have pro-
found neurologic symptoms.
Vasopressin antagonists
It is expected that V2 and V1/2 receptor antagonists will
make the treatment of hyponatremia more predictable,
more ‘titratable’, and less burdensome to patients, in com-
parison with the current therapeutic approach. Current
treatment usually consists primarily of fluid restriction,
and may be unacceptable to patients. Until now, five dif-
ferent oral, competitive, V2 and V1/2 vasopressin receptor
antagonists have been developed to the stage of clinical
testing17.
The treatment of hyponatremia will become more
promising when new oral vasopressin antagonists are
available. Whether such agents will also have an effect on
thirst, remains to be determined. Work must also be per-
formed to investigate the predictability of the correction
rate for given cases of hyponatremia when vasopressin
antagonists are used. No guidelines for prediction are
currently available. Another question is whether vaso-
pressin antagonists would lower the portal pressure in cir-
rhosis of the liver and whether they would increase the
glomerular filtration rate in patients with renal insuffi-
ciency. The final point concerns the role of hyponatremia
in the prognosis of advanced congestive cardiac failure. On
the basis of the potential reductions in cardiac pre- and
afterloads by V1/2 receptor antagonists, it is now conceiv-
able that hyponatremia may contribute to the severity of
congestive heart failure. In that case, vasopressin antago-
nists would accomplish substantially more than simply the
improvement of some cerebral symptoms. It will be nec-
essary to keep an open mind regarding the progress to be
expected in the clinical applications of oral vasopressin
antagonists17-19.
Prognosis
The prognosis depends on the underlying condition.
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Saæetak
SUSTAVNI PRISTUP BOLESNIKU S HIPONATRIJEMIJOM
I. RatkoviÊ-GusiÊ, P. Kes i V. BaπiÊ-Kes
Hiponatrijemija spada u najËeπÊe poremeÊaje elektrolita. Diferencijalna i konaËna dijagnoza su ponekad vrlo sloæene. Teπka
akutna hiponatrijemija je stanje s koncentracijom natrija niæom od 115 mmol/L, koje traje izmeu 36 i 48 sati. Ovo stanje
spada u hitna medicinska stanja, jer su bolesnici u opasnosti od prijeteÊeg edema mozga. Brzim ispravljanjem hiponatrijemije
do koncentracije od 130 mmol/L moæe se sprijeËiti trajno oπteÊenje mozga. KroniËna teπka hiponatrijemija praÊena je blaæim
simptomima i kod nje nema opasnosti od edema mozga. Mnogi autori preporuËuju ispravljanje po stopi od 0,5 mmol/sat do
konaËne koncentracije od 130 mmol/L. Na taj se naËin sprijeËava nastanak moædane mijelinolize, do koje moæe doÊi zbog
prebrzog ispravljanja kroniËne hiponatrijemije. U tijeku su brojni kliniËki pokusi o primjeni antagonista vazopresina u lijeËenju
hiponatrijemije. PoËetni rezultati su ohrabrujuÊi i ukazuju na njihovu uËinkovitost u poticanju izluËivanja tekuÊine iz tijela, kao
i na ispravljanje hiponatrijemije.
KljuËne rijeËi: Hiponatrijemija, dijagnostika; Hiponatrijemija, lijeËenje; Hiponatrijemija, komplikacije
